Compare ASRV & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | SCLX |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 52.9M |
| IPO Year | 1994 | N/A |
| Metric | ASRV | SCLX |
|---|---|---|
| Price | $3.66 | $7.42 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.9K | ★ 28.4K |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $14,634,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | $10.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.03 | $0.18 |
| 52 Week High | $3.93 | $34.27 |
| Indicator | ASRV | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 41.02 |
| Support Level | $3.65 | $4.56 |
| Resistance Level | $3.91 | $9.00 |
| Average True Range (ATR) | 0.13 | 0.66 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 29.63 | 18.19 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.